Represented Oklahoma Medical Research Foundation (OMRF) in a suit against Eli Lilly in the Western District of Oklahoma. OMRF alleged patent infringement and breach of a license agreement in connection with Eli Lilly's sales of Xigris, the first FDA-approved drug to treat severe sepsis. The suit settled on the eve of trial after more than 60 depositions, production of more than one million pages of documents by Eli Lilly, and a Markman hearing resulting in a claim construction favorable to our client.

Oklahoma Med. Research Found. v. Eli Lilly & Co., No. 01-0456 (W.D. Okla. filed Mar. 15, 2001).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Trademark portfolio management for one of the world's leading providers of lighting fixtures
Manages all aspects of the extensive trademark portfolio of one of the world's leading providers of lighting fixtures and related products and more
Represented financial institution in fair lending investigation
Advised a federally-chartered financial institution in connection with a fair lending investigation initiated by the OCC and referred to the more
Patent prosecution and counseling for OncImmune, a diagnostics start-up company
Represents OncImmune, a diagnostics start-up affiliated with the University of Nottingham, in obtaining patents for cancer diagnostic methods.  These more
White et al. v. Experian Information Solutions Inc., et al.
Represents Equifax in this putative class action filed in the United States District Court for the Central District of California. The more